A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma.

ABSTRACT: Renal cell carcinoma (RCC) is the deadliest form of urological cancer and is projected to be the fourth most common neoplasm in the USA in males by 2040. In addition to the current poor prognosis with 5-year survival rates hardly reaching 15%, the prevalence of resistance to currently available systemic therapies has also established an urgent need to develop new treatment regimen(s) for advanced RCC. Interferon-stimulated gene 15 (ISG15) is the first identified ubiquitin-like modifier and has been intensively studied for its central role in innate immunity against intracellular pathogens. However, in this study, we identified ISG15 as a novel tumor-associated antigen and prognostic marker in RCC. Further, we therapeutically targeted elevated ISG15 expression by means of a Listeria monocyt

SUBMITTER: Nguyen HM 

PROVIDER: S-EPMC10992556 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature